70
Growth Score
pts
Heat Score
11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
371175
2N Pharma develops novel therapeutic drugs for the treatment of ALS, Parkinson's and other neurodegenerative diseases.
- Preben Bruun-Nyzell: Chief Executive OfficerPast Role: Qatalum, Chief Financial Officer
About the Company
2N Pharma aims to give people with brain diseases new treatment options and renewed hope. The company develops novel, small molecule, disease-modifying drugs with initial focus on ALS and Parkinson's. 2N Pharma has received funding from the Novo Nordisk Foundation (through the BioInnovation Institute), the US Department of Defense
(CDMRP/ALSRP), Danish Growth Fund, and Innovation Fund Denmark. The company is based on published scientific work led by co-founder and CSO, Dr John Nieland.
